
[Federal Register Volume 76, Number 51 (Wednesday, March 16, 2011)]
[Notices]
[Pages 14407-14413]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-6079]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2011-N-0109]


Exchange of Letters Between Dr. Murray M. Lumpkin, Deputy 
Commissioner, International Programs, Food and Drug Administration and 
Mr. Martin Heraghty, Assistant Secretary General, Department of 
Agriculture, Fisheries and Food of Ireland Concerning Certification 
Requirements for Caseins, Caseinates, and Mixtures Thereof Exported 
From Ireland to the United States

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is providing notice of 
exchange of letters between Dr. Murray M. Lumpkin, Deputy Commissioner, 
International and Special Programs, FDA and Mr. Martin Heraghty, 
Assistant Secretary General, Department of Agriculture, Fisheries and 
Food (DAFF), concerning certification requirements for caseins, 
caseinates, and mixtures thereof exported from Ireland to the United 
States.
    The mutual goals of FDA and DAFF in establishing certification 
requirements for caseins, caseinates, and mixtures thereof exported 
from Ireland to the United States are to assure that contaminated 
products will not be imported into the United States and to minimize 
the need for extensive FDA audit sampling of these products from 
Ireland. DAFF and FDA have a history of cooperation on this issue and 
it is, therefore, desirable that the two Agencies continue to cooperate 
to maintain and improve consumer protection.

DATES: The agreement became effective November 10, 2010.

FOR FURTHER INFORMATION CONTACT: David P. Kelly, Office of 
International Programs, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 31, rm. 3404, Silver Spring, MD 20993-0002, 301-
796-8373, Fax: 301-595-7941.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 20.108(c), which 
states that all written agreements and understandings between FDA and 
others shall be published in the Federal Register, the Agency is 
publishing notice of this agreement.

    Dated: March 10, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
BILLING CODE 4160-01-P

[[Page 14408]]

[GRAPHIC] [TIFF OMITTED] TN16MR11.008


[[Page 14409]]


[GRAPHIC] [TIFF OMITTED] TN16MR11.009


[[Page 14410]]


[GRAPHIC] [TIFF OMITTED] TN16MR11.010


[[Page 14411]]


[GRAPHIC] [TIFF OMITTED] TN16MR11.011


[[Page 14412]]


[GRAPHIC] [TIFF OMITTED] TN16MR11.012


[[Page 14413]]


[GRAPHIC] [TIFF OMITTED] TN16MR11.013

[FR Doc. 2011-6079 Filed 3-15-11; 8:45 am]
BILLING CODE 4160-01-C


